Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bever, C. T.
Right arrow Articles by Johnson, K. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bever, C. T., Jr.
Right arrow Articles by Johnson, K. P.
NEUROLOGY 1991;41:1124
© 1991 American Academy of Neurology

Gamma-interferon induction in patients with chronic progressive MS

C. T. Bever, Jr., MD, H. S. Panitch, MD, H. B. Levy, PhD, D. E. McFarlin, MD; and and K. P. Johnson, MD

Department of Neurology (Drs. Bever, Panitch, and Johnson), University of Maryland School of Medicine, Baltimore, MD; the Research Service (Drs. Bever and Panitch), DVA Medical Center, Baltimore, MD; the Laboratory of Viral Diseases (Dr. Levy), NIAID, Frederick, MD; and the Neuroimmunology Branch (Dr. McFarlin), NINDS, Bethesda, MD.

Although gamma interferon ({gamma}-IFN) may be involved in the pathogenesis of exacerbations of multiple sclerosis (MS), whether it plays a role in chronic progressive MS is not known. To investigate this, we retrospectively analyzed serum samples from nine chronic progressive MS patients who were treated with monthly intravenous infusions of the interferon inducer polyinosinic acid polycytidylic acid polylysine in carboxymethylcellulose (poly ICLC). Using a bioassay we found that the mean peak total interferon level was 177 U/ml 12 hours after infusion, and using a radioimmunoassay we found that the mean peak {gamma}-IFN level was 15.9 U/ml 12 hours after infusion, so that {gamma}-IFN made up approximately 10% of the total. Greater {gamma}-IFN induction did not correlate with clinical worsening; induced {gamma}-IFN levels were not higher in two patients who worsened on treatment, and the highest levels were found in a patient who remained stable. Either chronic progressive MS is not sensitive to {gamma}-IFN or the effects of {gamma}-IFN are masked by other mediators induced by poly ICLC.

Address correspondence and reprint requests to Dr. C.T. Bever, Jr., Department of Neurology, UMH, N4W46, 22 South Greene St., Baltimore, MD 21201.

Dr. Bever is the recipient of a career development award from the Department of Veterans Affairs.

Presented in part at the 42nd annual meeting of the American Academy of Neurology, Miami Beach, FL, May 1990.

Received September 12, 1990. Accepted for publication in final form December 11, 1990.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
C. M. Pelfrey, R. A. Rudick, A. C. Cotleur, J.-C. Lee, M. Tary-Lehmann, and P. V. Lehmann
Quantification of Self-Recognition in Multiple Sclerosis by Single-Cell Analysis of Cytokine Production
J. Immunol., August 1, 2000; 165(3): 1641 - 1651.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by AAN Enterprises, Inc.